Although various chemical interventions are being developed to treat gastric cancer, there is a constant demand for research into new GC treatment targets and modes of action (MOAs) because of the low effectiveness and side effects of current treatments.<h4>Methods</h4>Using the TCGA data portal, we identified EHMT2 overexpression in GC samples. This evidence concerns the gene EHMT2 and gastric cancer.